Kooperativer Bibliotheksverbund

UID:

Format: XII, 301 Seiten , Ill., graph. Darst.

ISBN: 9781603272704

Series Statement: Cancer drug discovery and development

Note: Text engl.

Language: English

Keywords: Krebs 〈Medizin〉 ; Sirolimus ; Targeted drug delivery

UID:

Format: XVIII, 536 Seiten , Ill.

Edition: 1st ed.

ISBN: 9780387690605 , 0387690603

Note: Text engl.

Language: English

Keywords: Kind ; Krebs 〈Medizin〉 ; Aufsatzsammlung ; Aufsatzsammlung ; Aufsatzsammlung

UID:

Format: VII, 364 S. : Ill., graph. Darst.

ISBN: 0-8493-7291-7

Series Statement: Pharmacology and toxicology

Language: English

Subjects: Medicine

Keywords: Cytostatikum ; Arzneimittelresistenz ; Cytostatikum ; Pharmakologie

URL: http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=005749419&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA

UID:

Format: 189 Seiten , Illustrationen , 20 cm x 14.5 cm

ISBN: 9783730605707 , 3730605704

Content: Dieses durchgehend illustrierte Buch versammelt die spannendsten Outdoor-Aktivitäten für Kinder zwischen 3 und 11 Jahren. Von Spielen über kreative Bastelarbeiten bis hin zu Survival-Tipps. Die Natur bietet unzählige Möglichkeiten für Spiele, Entdeckungen und Erlebnisse. Die Waldschul-Bewegung greift darauf zurück und stärkt Selbstbewusstsein und Selbstwertgefühl von Kindern durch praktische Lernerfahrungen in der Natur. Ob allein, mit der Familie oder in der Gruppe – die besten Abenteuer warten direkt vor der Tür!

Language: German

Keywords: Ratgeber

Author information: Mayer, Felix

UID:

Format: XVIII, 536 p. , online resource.

Edition: 1st ed. 2010.

ISBN: 9780387690629

Content: Molecularly-Targeted Therapy for Childhood Cancer is a comprehensive exploration of the molecular aspects of childhood cancers that are currently being targeted therapeutically or are in the early phases of development. Each chapter describes key molecular characteristics of hematopoietic malignancies and solid tumors in children and young adults that are fundamental to the etiology, survival and drug resistance of these cancers as well as able to serve as tumor selective pathways for treatment. There has never been a more optimal time to explore the current and future use of molecularly targeted therapies in pediatric oncology. Conventional chemotherapeutic approaches have been dose intensified to such an extent that acute and late toxicities have reached maximal points while the rate of cure has slowed. The volume moves beyond conventional chemotherapeutic approaches to explore approaches that target tumor selective molecular and immunologic characteristics. The chapters further explore how such targeted therapies can begin to be integrated with conventional regimens in order to improve efficacy while reducing morbidity. While molecularly targeted therapies have generated great excitement in the world of oncology, their impact for pediatric patients may provide some of the greatest impact in part because of their developmental susceptibilities to conventional cytotoxic treatments. In addition, less toxic and more effective therapies hold great promise for improving the outcome of pediatric patients in developing countries where supportive care measures may not always be optimal. Molecularly-Targeted Therapy for Childhood Cancer is thus a timely first foray into the world of targeted, pathway directed treatment approaches for pediatric patients with cancer and brings us one step closer to the day when Paul Erhlich's hope for therapeutic Magic Bullets becomes the conventional approach to cure.

Note: Hematologic Malignancies -- The Emerging Era of Targeted Therapy in Childhood Acute Lymphoblastic Leukemia -- Molecular Targeted Therapies in T-Cell Acute Lymphoblastic Leukemia -- Molecularly Targeted Therapy for Infant ALL -- Targeted Therapeutic Approaches for AML -- Acute Promyelocytic Leukaemia -- Down Syndrome and Acute Myeloid Leukemia: An Unique Genetic Sensitivity to Chemotherapy -- Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia (JMML) -- Chronic Myeloid Leukemia: Pathophysiology and Therapeutics -- Molecularly Targeted Therapies in Pediatric Myelodysplastic Syndromes -- New Therapeutic Frontiers for Childhood Non-Hodgkin Lymphoma -- Molecular Targeting of Post-transplant Lymphoproliferative Disorders -- Solid Tumors -- Molecularly Targeted Therapies for Astrocytomas -- Targeted Therapy in Medulloblastoma in Molecularly Targeted Therapy for Childhood Cancer -- Future Treatments of Ependymoma -- Development of Targeted Therapies for Rhabdoid Tumors Based on the Functions of INI1/hSNF5 Tumor Suppressor -- Development of Targeted Therapies for Neurofibromatosis Type 1 (NF1) Related Tumors -- Molecular Therapy for Neuroblastoma -- Ewing's Sarcoma Family of Tumors: Molecular Targets Need Arrows -- Molecular Targeted Therapy for Wilms' Tumor -- Molecular Therapy for Rhabdomyosarcoma -- Molecularly Targeted Therapy for Osteosarcoma: Where Do We Go from Here? -- Nonrhabdomyosarcoma Soft Tissue Sarcoma in Children: Developing New Treatments Based on a Better Understanding of Disease Biology.

In: Springer Nature eBook

Additional Edition: Printed edition: ISBN 9780387690605

Additional Edition: Printed edition: ISBN 9780387564944

Additional Edition: Printed edition: ISBN 9781489981424

Language: English

DOI: 10.1007/978-0-387-69062-9

URL: https://doi.org/10.1007/978-0-387-69062-9

UID:

Format: Online-Ressource , v.: digital

Edition: Online-Ausg. Springer eBook Collection. Biomedical and Life Sciences Electronic reproduction; Available via World Wide Web

ISBN: 9780387690629

Content: Each chapter will focus on the known molecular characteristics of specific childhood cancers, focusing on how the molecular 'drivers' can be exploited from a therapeutic standpoint with currently available targeted agents. Where applicable, integration of targeted therapies with conventional cytotoxic agents will be considered. This volume will provide a comprehensive summary of molecular characteristics of childhood cancers, and how the changes involved in transformation provide us with opportunities for developing relatively less toxic, but curative, therapies.

Content: Each chapter will focus on the known molecular characteristics of specific childhood cancers, focusing on how the molecular 'drivers' can be exploited from a therapeutic standpoint with currently available targeted agents. Where applicable, integration of targeted therapies with conventional cytotoxic agents will be considered. This volume will provide a comprehensive summary of molecular characteristics of childhood cancers, and how the changes involved in transformation provide us with opportunities for developing relatively less toxic, but curative, therapies

Note: Includes bibliographical references and index , The Emerging Era of Targeted Therapy in Childhood Acute Lymphoblastic Leukemia; The BCR/ABL Tyrosine Kinase and Ph+ ALL; The FLT-3 Pathway in MLL Rearranged Infant ALL; The Notch Pathway in T-ALL; Monoclonal Antibodies in the Treatment of ALL; Cancer Stem Cells in ALL; Summary; References; Molecular Targeted Therapies in T-CellAcute Lymphoblastic Leukemia; Introduction; Oncogenic Transcription Factors; NOTCH1; The NOTCH1 Pathway; Strategies for NOTCH1 Inhibition; Resistance to NOTCH1 Inhibitors and Therapeutic Strategies to Overcome Resistance; PTEN, PI3K-AKT, and mTOR; Tyrosine Kinase Genes , RASConclusions; References; Molecularly Targeted Therapy for Infant ALL; FLT3 Tyrosine Kinase Inhibition; Targeting Anti-apoptotic BCL-2 Family Members; Targeting MLL Fusion Transcripts; PFWT Targeting of MLL Partner Protein Interactions; Targeting Glycogen Synthase Kinase 3; HSP90 as a Potential Therapeutic Target; Epigenetic Strategies; mTOR Inhibition; Targeting CD33 Cell Surface Antigen; Conclusions; References; Targeted Therapeutic Approaches for AML; Introduction; Mechanisms of Leukemogenesis: Implications for Targeted Therapy Development , Refining the Definition and Relevance of Targeted TherapyDevelopment of Targeted Therapies for AML; Specific Examples of Targeting AML; Targeting Pathways that Alter Leukemia Cell Proliferation and Survival; Tyrosine Kinases; Inhibition of Signaling Pathways Downstream of TK Receptors; Drug Resistance Mechanisms and Leukemic Cell Survival; Epigenetic and Chromatin Remodeling-Directed Targets; Targeted Immunotherapy and Immunostimulatory Therapy; Future Challenges; References; Acute Promyelocytic Leukaemia; Introduction; Demographic Features; Pathogenesis of APL; Diagnosis of APL , Treatment of APLInduction Therapy; Complications of Induction Therapy; Consolidation Therapy; Maintenance Treatment; Molecular Monitoring in APL; MRD Detection Is an Independent Predictor of Outcome in APL; Real-Time Quantitative RT-PCR Assays Enhance MRD Detection in APL; Anthracycline Cumulative Dose and Cardiotoxicity; Stem Cell Transplantation; Arsenic Trioxide; What to Do When Treatment Fails?; Extramedullary Relapse; New Drugs; Conclusions; References; Down Syndrome and Acute Myeloid Leukemia: An Unique Genetic Sensitivity to Chemotherapy; Introduction , Chemotherapy Sensitivity and Down SyndromeThe Role of Chromosome 21-Localized Genes and Chemotherapy Sensitivity in Down Syndrome AMkL; Relationship Between GATA1 and Chemotherapy Drug Sensitivities; Differential Gene Expression Studies and Down Syndrome AMkL; Future Challenges; Conclusion; References; Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia (JMML); GM-CSF and Deregulated RAS Signaling in Pathogenesis of JMML; Mouse Models; Targeted Therapeutics; RAF/MEK/ERK; PI3K/AKT/mTOR; PTPN11/SHP-2; JAK2-STAT5; Conclusion; References , Chronic Myeloid Leukemia: Pathophysiology and Therapeutics , Electronic reproduction; Available via World Wide Web

Additional Edition: ISBN 9780387690605

Language: English

DOI: 10.1007/978-0-387-69062-9

URL: Volltext  (lizenzpflichtig)